Literature DB >> 31336526

Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: A cross-sectional study in north of Iran.

Fariborz Mansour-Ghanaei1, Farahnaz Joukar2, Sahar Najafi Mobaraki1, Sara Mavaddati3, Soheil Hassanipour4, Masood Sepehrimanesh5.   

Abstract

BACKGROUND AND AIM: The aim of this study was to describe the frequency of non-alcoholic fatty liver disease (NAFLD) in patients with diabetes mellitus (DM), hyperlipidemia, obesity and polycystic ovaries syndrome (PCOS).
METHODS: In a cross-sectional study, 333 patients who had one of the certain diagnosis of DM, hyperlipidemia, obesity or PCOS were enrolled. Information about demographics, anthropometric, nutritional habitude, smoking history, medical history and physical activity were recorded. Liver ultrasound examination and routine biochemistry analysis were performed.
RESULTS: Among 333 patients with one of the four above-mentioned diseases. 199 patients (59.8%) had NAFLD. Male were more likely to have NAFLD than female (72.8% vs. 50.8% respectively, P < 0.001). About, 80.7% of patients through 41-50 years age had NAFLD. The frequency of abnormal fasting blood glucose, alanine aminotransferase (ALT), triglyceride, and total cholesterol were significantly higher in patients with NAFLD (P < 0.05). Subjects with NAFLD had a higher body mass index than non-NAFLD (33.6 ± 7.9 kg/m2 vs. 31.1 ± 5.0 kg/m2 respectively, P = 0.002). Patients with DM, hyperlipidemia, hypertension, and hypothyroidism were more likely to have NAFLD (P < 0.05). Patients with consumption of supper, high-fat diet, enjoy of eating and smoking were more likely to have NAFLD and patients with fruit and vegetable uptake and physical activity were less likely to have NAFLD (P < 0.05).
CONCLUSIONS: As most patients with NAFLD are asymptomatic, employed individuals with higher education levels, with a history of smoking and unhealthy diet along with DM, hyperlipidemia, PCOS and obesity seriously have to be followed and educated for lifestyle modification.
Copyright © 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diabetes mellitus; Hyperlipidemia; Non-alcoholic fatty liver disease; Obesity; Polycystic ovaries syndrome

Year:  2019        PMID: 31336526     DOI: 10.1016/j.dsx.2019.03.009

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  10 in total

1.  Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in Type 2 Diabetes.

Authors:  Chenxi Wang; Zhensheng Cai; Xia Deng; Haoxiang Li; Zhicong Zhao; Chang Guo; Panpan Zhang; Lian Li; Tian Gu; Ling Yang; Li Zhao; Dong Wang; Guoyue Yuan
Journal:  Int J Med Sci       Date:  2021-07-23       Impact factor: 3.738

Review 2.  The burden and risks of emerging complications of diabetes mellitus.

Authors:  Dunya Tomic; Jonathan E Shaw; Dianna J Magliano
Journal:  Nat Rev Endocrinol       Date:  2022-06-06       Impact factor: 47.564

3.  Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.

Authors:  Qiumei Zhou; Yulong Wang; Jiajia Wang; Yating Liu; Dehui Qi; Wei Yao; Hui Jiang; Tingting Li; Kaiquan Huang; Wancun Zhang; Xingxing Huo
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

4.  Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.

Authors:  Ali Mahmoudi; Alexandra E Butler; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Biomed Res Int       Date:  2021-12-26       Impact factor: 3.411

5.  Dietary supplements consumption and its association with socioeconomic factors, obesity and main non-communicable chronic diseases in the north of Iran: the PERSIAN Guilan Cohort Study (PGCS).

Authors:  Marjan Mahdavi-Roshan; Arezoo Rezazadeh; Farahnaz Joukar; Yasaman Khorshidi; Mohammadreza Naghipour; Fariborz Mansour-Ghanaei
Journal:  BMC Nutr       Date:  2021-12-15

6.  The Risk Factors of Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients Undergoing Bariatric Surgery in Iran.

Authors:  Ladan Aghakhani; Neda Haghighat; Masoud Amini; Seyed Vahid Hosseini; Seyed Jalil Masoumi
Journal:  Gastroenterol Res Pract       Date:  2022-02-07       Impact factor: 2.260

7.  Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis.

Authors:  Ali Mahmoudi; Alexandra E Butler; Muhammed Majeed; Maciej Banach; Amirhossein Sahebkar
Journal:  Nutrients       Date:  2022-03-22       Impact factor: 5.717

Review 8.  Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models.

Authors:  Ali Mahmoudi; Seyed Adel Moallem; Thomas P Johnston; Amirhossein Sahebkar
Journal:  PPAR Res       Date:  2022-06-17       Impact factor: 4.385

9.  Decreased inflammatory gene expression accompanies the improvement of liver enzyme and lipid profile following aerobic training and vitamin D supplementation in T2DM patients.

Authors:  Rastegar Hoseini; Hiwa Ahmed Rahim; Jalal Khdhr Ahmed
Journal:  BMC Endocr Disord       Date:  2022-10-08       Impact factor: 3.263

10.  Correlation between the small dense LDL level and nonalcoholic fatty liver disease: Possibility of a new biomarker.

Authors:  Ha Won Hwang; Jung Hwan Yu; Young-Joo Jin; Young Ju Suh; Jin-Woo Lee
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.